The results of the in vitro doxorubicin sensitivity assay using Ly10 cells (wild-type TP53 DLBCL cell line) expressing mutant p53 showed that the R273C and R282Q mutants had reduced sensitivity to doxorubicin, with 2.28- and 2.23-fold increases in IC50, respectively (Figure 8). This evidence concerns the gene TP53 and diffuse large B-cell lymphoma.